高脂饮食诱导小鼠模型中胰高血糖素样肽-1受体与胰高血糖素受体双激动剂治疗后肝脏脂肪与铁的多参数MRI评估
研究在高脂饮食小鼠模型中使用9.4-T MRI定量评估GLP-1R/GCGR双激动剂(mazdutide)与GLP-1R单激动剂(semaglutide)对肝脏脂肪和铁含量的疗效。治疗4周后,双激动剂组PDFF较基线的降幅大于单激动剂组(中位变化-5.59% vs -3.30%,P=0.02),而R2*降幅在两组间1周和4周均无显著差异。肝脏PDFF与肝甘油三酯水平(r=0.82)和组织学脂肪变评分(r=0.81)正相关,R2*值与PDFF亦相关(r=0.69)。
要点
- 高脂饮食小鼠治疗4周后,双激动剂组PDFF降幅大于单激动剂组(中位-5.59% vs -3.30%,P=0.02)。
- 两组R2*降幅在治疗1周和4周均无显著差异(1周P=0.50,4周P=0.41)。
- 肝脏PDFF与肝甘油三酯水平(r=0.82)及组织学脂肪变评分(r=0.81)正相关。
核心结论
- 超高场强MRI结合组织学分析显示,在高脂饮食小鼠模型中,GLP-1R/GCGR双激动剂较GLP-1R单激动剂更有效减少肝脏脂肪蓄积,MRI衍生的肝脏PDFF和R2*值与组织学表现相关。
研究设计与样本
- 研究为高脂饮食诱导小鼠模型研究,42只雄性小鼠高脂饮食13周后皮下注射双激动剂mazdutide、单激动剂semaglutide或磷酸盐缓冲液对照,每3天一次共4周;对照组另含14只年龄匹配标准饲料雄性小鼠接受磷酸盐缓冲液;使用9.4-T MRI扫描仪于基线及治疗后1周和4周行MRI扫描并取组织样本。
诊断标准与关键数值
- MRI衍生质子密度脂肪分数(PDFF)定量肝脏脂肪含量,R2*定量肝脏铁含量;治疗4周双激动剂组PDFF较基线中位变化-5.59%(IQR -6.80, -3.84)vs 单激动剂组-3.30%(IQR -3.80, -2.82),P=0.02;治疗1周两组PDFF较基线中位变化-2.15%(IQR -5.10, -1.69)vs -1.24%(IQR -2.95, -0.78),P=0.19;治疗1周两组R2*较基线中位变化-53.86 Hz(IQR -76.79, -43.19)vs -46.17 Hz(IQR -68.01, -35.04),P=0.50;治疗4周两组R2*较基线中位变化-67.00 Hz(IQR -79.33, -44.66)vs -57.18 Hz(IQR -78.51, -12.85),P=0.41。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Glucagon-like peptide-1 receptor (GLP-1R) and glucagon receptor (GCGR) dual agonist, along with GLP-1R monoagonist, show promise in treating metabolic dysfunction-associated steatotic liver disease (MASLD). Liver fat and iron content are important surrogate markers for disease assessment. However, it remains unclear whether dual agonists provide superior therapeutic benefit over monoagonists for hepatic fat and iron regulation. Purpose To evaluate whether a GLP-1R/GCGR dual agonist offers greater therapeutic efficacy in reducing hepatic fat and iron content compared with a GLP-1R monoagonist in a high-fat diet mouse model using quantitative 9.4-T MRI. Materials and Methods Forty-two male mice were fed a high-fat diet for 13 weeks and then were treated subcutaneously with GLP-1R/GCGR dual agonist (mazdutide), GLP-1R monoagonist (semaglutide), or phosphate-buffered saline (control) every 3 days for 4 weeks. The control group included 14 age-matched male mice that received a standard chow diet and phosphate-buffered saline treatment. MRI scans and tissue samples were obtained at baseline and at 1 and 4 weeks after treatment. MRI-derived proton density fat fraction (PDFF), quantifying hepatic fat content, and R2*, quantifying hepatic iron content, were derived with a 9.4-T MRI scanner. Reductions in PDFF and R2* were compared among the groups using analysis of covariance and Student t tests. Correlations between imaging parameters and histologic analyses were evaluated using Pearson or Spearman correlation coefficients. Results After 4 weeks of treatment, mice treated with the dual agonist showed a greater reduction in PDFF from baseline values compared with mice treated with the monoagonist (median change, -5.59% [IQR, -6.80, -3.84] vs -3.30% [IQR, -3.80, -2.82]; P = .02). At 1 week after treatment, there was no evidence of a difference in PDFF reduction from baseline between the two groups (median change, -2.15% [IQR, -5.10, -1.69] vs -1.24% [IQR, -2.95, -0.78]; P = .19). Decreases in R2* values from baseline were also not significantly different between the groups at 1 week (median change, -53.86 Hz [IQR, -76.79, -43.19] vs -46.17 Hz [IQR, -68.01, -35.04]; P = .50) and 4 weeks (median change, -67.00 Hz [IQR, -79.33, -44.66] vs -57.18 Hz [IQR -78.51, -12.85]; P = .41) after treatment. Liver PDFF was positively correlated with hepatic triglyceride levels (r = 0.82; P < .001) and histologic steatosis scores (r = 0.81; P < .001), as well as R2* values (r = 0.69; P < .001). Conclusion Ultrahigh-field-strength MRI combined with histologic analyses demonstrated that the GLP-1R/GCGR dual agonist more effectively reduced hepatic fat accumulation compared with the GLP-1R monoagonist in a high-fat diet mouse model. MRI-derived liver PDFF and R2* values were correlated with histologic findings. Published under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Yin in this issue.
引用
- Xia H, Min Y, Wang Y, et al. Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model. Radiology. 2025. PMID: 40828048. doi:10.1148/radiol.243780
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。